Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/32327

Multimorbidity and psychotropic polypharmacy among participants with autism spectrum disorder with intellectual disability


no-thumbnailView/Open:

 Multimorbidity and psychotropic polypharmacy among participants with.pdf



887,6 kB
Adobe PDF
Share:

This resource is restricted

Title:
Multimorbidity and psychotropic polypharmacy among participants with autism spectrum disorder with intellectual disability
Authors:
Espadas, Cristina
Ballester, Purificación
Londoño, Ana Carolina
Almenara, Susana
Aguilar, Víctor  
Belda, César
Pérez, Enrique
Peiró, Ana  
Editor:
Elsevier
Department:
Departamentos de la UMH::Farmacología, Pediatría y Química Orgánica
Issue Date:
2020-07
URI:
https://hdl.handle.net/11000/32327
Abstract:
Nowadays, adults with autism spectrum disorder (ASD) experience several comorbidities whose treatment implies a wide range of psychotropic prescriptions. This study aimed to evaluate medication-related safety, drugdrug interactions, and psychotropics prescription trends. We conducted an observational and multicentric pharmacovigilance study in subjects with ASD and Intellectual disability (ID, n = 83). Clinical information (diagnoses, ongoing medications, comorbidities [multimorbidity ≥ 4 chronic health conditions]) and psychotropic prescriptions (polypharmacy ≥ 4 chronic drugs, daily drug doses, co-prescription) were registered. Ethical approval for this study was obtained. Participants (30±10 years old, 86% men, BMI 27±6 kg/m2) displayed 37% multimorbidity (mean of 3, IQR 2–4), and 57% polypharmacy (13% out of dose recommended range). Most drugs prescribed were psychotropic risperidone which is related to nervous system comorbidities (18% epilepsy, 16% insomnia, and 14% psychotic agitations). Risperidone and quetiapine were co-prescribed in 60% of the cases without any monitoring adverse event routine. The rates of multimorbidity and polypharmacy, among our young adults with ASD and ID, are concerning. Data suggest the need to develop a pharmacovigilance monitoring system to evaluate prescription accuracy, long-term safety of ongoing medications, and the fixed doses in this autistic population with associated ID.
Keywords/Subjects:
Autism spectrum disorder
Intellectual disability
Polypharmacy
Adverse events
Pharmacovigilance
Multimorbidity
Type of document:
application/pdf
Access rights:
info:eu-repo/semantics/closedAccess
DOI:
https://doi.org/10.1016/j.psychres.2020.113321
Appears in Collections:
Artículos Farmacología, Pediatría y Química Orgánica



Creative Commons ???jsp.display-item.text9???